Boston Scientific Suit Says J&J’s Cypher Infringes Patent, Asks For Injunction
This article was originally published in The Gray Sheet
Executive Summary
Opposing patent infringement claims by Boston Scientific and Johnson & Johnson introduce a level of uncertainty as to which firm will initially capture the lion's share of the U.S. drug-eluting stent market
You may also be interested in...
Cordis Beats Boston Scientific In Latest Round Of DES Patent Suits
A jury will convene in August to set damages for Boston Scientific's infringement of J&J/Cordis' coronary and peripheral stent patents
Cordis Beats Boston Scientific In Latest Round Of DES Patent Suits
A jury will convene in August to set damages for Boston Scientific's infringement of J&J/Cordis' coronary and peripheral stent patents
Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents